Vuong Trieu Buys Shares of Oncotelic Therapeutics, Inc. $OTLC
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Vuong Trieu, CHAIRMAN AND CEO at Oncotelic Therapeutics, Inc. ($OTLC), bought 239,759 shares at an average price of $0.04, for a total transaction of $9,590.36. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Oncotelic Therapeutics, Inc. Stock Up 50.0%
Shares of Oncotelic Therapeutics, Inc. ($OTLC) traded around $0.04 on Thursday, up 50.0% for the day.
Oncotelic Therapeutics, Inc. Earnings
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications in the United States. The company develops antisense and small molecule injectable drugs for the treatment of cancer. It is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer, melanoma, and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, the company develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson's disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies, as well as nanoparticle products for the treatment of various cancers. The company is based in Agoura Hills, California.
Get Oncotelic Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OTLC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.